文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

镰状细胞病与地中海贫血患者接受干细胞移植或基因治疗后的生活质量系统综述

A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy.
PubMed 文献 · Blood Adv · 2021-01-01

该系统综述评估了造血干细胞移植(HSCT)和基因治疗对镰状细胞病(SCD)及地中海贫血患者健康相关生活质量(HRQOL)的影响。纳入16项研究共517例参与者,HSCT在多数HRQOL领域显示小到大的正向效应(Cohen's d均值0.47),基因治疗初步数据显示改善。证据质量以中等为主(81%),需更多纵向研究验证可持续性。

要点

  • HSCT在SCD和地中海贫血患者中与多个HRQOL领域的正向改善相关。
  • 地中海贫血患者HSCT在躯体和情感领域效应量大(中位d=0.79和0.57)。
  • 基因治疗初步数据显示HRQOL改善,但需更多纵向研究验证。

核心结论

  • HSCT对SCD和地中海贫血患者的多个HRQOL领域有积极影响,但需更多纵向研究评估效应可持续性。
  • 基因治疗在SCD和地中海贫血中显示HRQOL改善的初步数据,持续报告试验结果是关键。

研究设计与样本

  • 系统综述,检索医学文献数据库,纳入16项研究(地中海贫血9项、SCD 6项、两者1项),共517例参与者(地中海贫血416例、SCD 101例)。

主要发现

  • HSCT在多数HRQOL领域显示小到大的正向效应(Cohen's d均值0.47,中位数0.37,范围0.27-2.05)。
  • 地中海贫血中HSCT在躯体和情感领域常见大效应(中位d分别为0.79和0.57)。
  • SCD中HSCT在所有HRQOL领域均与大正向效应相关。
  • 基因治疗在SCD和地中海贫血中显示跨领域HRQOL改善的初步数据。
  • 13项研究(81%)的证据质量为中等。

临床怎么用

  • HSCT可作为改善SCD和地中海贫血患者HRQOL的治疗选择之一,需结合个体情况评估。
  • 关注基因治疗试验中HRQOL结局的报告,以全面理解其获益。

局限性

  • 需更多纵向研究评估HSCT对HRQOL效应的可持续性。
  • 基因治疗数据为初步的,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with sickle cell disease (SCD) and thalassemia experience several complications across their lifespan that lead to impairment in different health-related quality of life (HRQOL) domains. There is increasing interest in curative therapies for patients with SCD and thalassemia, including hematopoietic stem cell transplant (HSCT) and gene therapy; however, the effect of these therapies on various HRQOL domains remains unclear. Our objective was to systematically evaluate the most recent evidence for the effect of HSCT and gene therapy on HRQOL in patients with SCD and thalassemia. A systematic search of medical literature databases was conducted. A total of 16 studies (thalassemia, n = 9; SCD, n = 6; both, n = 1) involving 517 participants met inclusion criteria (thalassemia, n = 416; SCD, n = 101). HSCT was associated with a small to large positive effects in most HRQOL domains (Cohen's d; mean = 0.47; median = 0.37; range, 0.27-2.05). In thalassemia, HSCT was frequently associated with large positive effects in physical and emotional HRQOL domains (median d = 0.79 and d = 0.57, respectively). In SCD, HSCT was associated with large positive effects in all HRQOL domains. Emerging data suggest improvement in HRQOL outcomes across different domains following gene therapy in thalassemia and SCD. The quality of evidence was moderate in 13 studies (81%). HSCT has a positive impact on several HRQOL domains in patients with SCD and thalassemia; however, more longitudinal studies are warranted to assess the sustainability of these effects. Reporting HRQOL outcomes from ongoing gene therapy or gene-editing trials in SCD and thalassemia is key to better understand the benefits of such therapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Badawy SM, Beg U, Liem RI, et al. A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Adv. 2021. PMID: 33496753. doi:10.1182/bloodadvances.2020002948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。